Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.

Clinical chemistry - 1 Dec 2008

Clark Jarrod P, Munson Kristofer W, Gu Jessie W, Lamparska-Kupsik Katarzyna, Chan Kevin G, Yoshida Jeffrey S, Kawachi Mark H, Crocitto Laura E, Wilson Timothy G, Feng Ziding, Smith Steven S

Abstract excerpt

BACKGROUND: TMPRSS2:ERG fusions are promising prostate cancer biomarkers. Because they can occur in multiple forms in a single cancer specimen, we developed a quantitative PCR test that detects both type III and type VI TMPRSS2:ERG fusions. The assay is quantified from a standard curve determined with a plasmid-cloned type III TMPRSS2:ERG fusion target. METHODS: We collected expressed prostatic secretion (EPS)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenomatous Polyposis Coli Protein
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Glutathione S-Transferase pi

Share to Oncogene Proteins, Fusion

Share to Prostate-Specific Antigen

Share to Receptors, Retinoic Acid

Share to Ultrasonography

Source

Open in PubMed Open full text

Identifiers

PMID: 18948370
DOI: 10.1373/clinchem.2008.108845
PMCID: PMC2977928

Genes

ERG
TMPRSS2
APC
GSTP1
RARB
RASSF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.PMID 18948370Read ↗

Molecular Diagnosis of Prostate Cancer: <i>PCA3</i> and <i>TMPRSS2:ERG</i> Gene FusionSemantic proximity Read ↗

Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.Semantic proximity Read ↗

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.Semantic proximity Read ↗

Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.Semantic proximity Read ↗

Exploring therapeutic applications of PTEN, TMPRSS2:ERG fusion, and tumour molecular subtypes in prostate cancer managementSemantic proximity Read ↗

PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate CancerSemantic proximity Read ↗

Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate CancerSemantic proximity Read ↗

Clinical Applications of Novel ERG Immunohistochemistry in Prostate Cancer Diagnosis and ManagementSemantic proximity Read ↗

Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature ReviewSemantic proximity Read ↗

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signalingSemantic proximity Read ↗

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.Semantic proximity Read ↗

Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.